| Biomarker ID | 1188 |
| PMID | 23918943 |
| Year | 2013 |
| Biomarker | Methylation Status of C1orf114 (High vs. Low) |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Lower Methylation in Patients with Longer Survival |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1: Univariate: [HR= 2.77 (95% CI: 1.93-3.98), p-value <0.001, AUC=0.67)]; Multivariate: [1.97 (95 % CI: 1.31-2.94), p-value= 0.001 ]; Cohort 2: Univariate: [HR= 2.105 (1.212-3.656), p-value= 0.008, AUC = 0.60]; Multivariate: [HR= 1.816 (1.006-3.279), p-value= 0.048, AUC=0.85] |
| Effect on Pathways | Pathways include: CACNA1D knockdown 96h PC3, CHEK2 knockdown 96h A549, NR2C1 knockdown 96h HCC515 , CAMK2D knockdown 96h PC3, SNRK knockdown 96h PC3 |
| Experiment | Biochemical recurrence |
| Type of Biomarker | Prognostic |
| Cohort | Nonmalignant samples [(adjacent normal [ADJ-N], benign prostatic hyperplasia (BPH)( n = 35)] and radical prostatectomy (RP) samples (n = 293) were chosen for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.892 |
| Accuracy | NA |
| Level Of Significance | P < 0.001 |
| Method Used | quantitative methylation specific PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | C1orf114 |